Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31220447 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL8224022 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL20993818 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL6181712 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL13827783 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL3133278 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL16488769 | 1.00 | CTSS (0.56) | CTSSCTSLSYKPPARAKLK5 | |
| Hydrochloric Acid SCHEMBL28347449 | 0.99 | CTSS (0.55) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL12873000 | 0.91 | KLK5 (0.57) | CTSSCTSLSYKPPARAKLK5 | |
| SCHEMBL6388701 | 0.91 | KLK5 (0.57) | CTSSCTSLSYKPPARAKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | AVACTA LIFE SCIENCES, LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-10414731-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20180346424-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| EP-1992611-B1 | ISODIPEPTIDE USEFUL AS A SYNTHETIC UNIT FOR MAKING PEPTIDES | KISO YOSHIAKI (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100152418-A1 | Switch-Peptides as Tool for the Study of Fibrillogenesis | EPFL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20090318669-A1 | Novel Isodipeptide | KISO YOSHIAKI | 2009-12-24 | — | — | US | disclosed |
| EP-1992611-A1 | NOVEL ISODIPEPTIDE | Kiso, Yoshiaki (JP) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | CD47, VCAM1, CD44 | CTSS 215/4885CTSL 146/4885SYK 365/4885 |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | CTSS 1013/4885CTSL 327/4885SYK 1276/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | CTSS 1219/4885CTSL 1135/4885SYK 1895/4885 |
| US-20090318669-A1 | Novel Isodipeptide | VIP, IAPP, ANPEP | CTSS 2372/4885CTSL 50/4885SYK 2176/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CTSS 471/4885CTSL 223/4885SYK 1914/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CTSS 471/4885CTSL 223/4885SYK 1914/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | CTSS 320/4885CTSL 100/4885SYK 4442/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | CTSS 320/4885CTSL 100/4885SYK 4442/4885 |
| US-10414731-B2 | Substituted oxopyridine derivatives | OGFOD1, PNPO, PTGIS | CTSS 4264/4885CTSL 2306/4885SYK 911/4885 |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | CTSS 717/4885CTSL 909/4885SYK 569/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | CTSS 2162/4885CTSL 2233/4885SYK 1048/4885 |
| US-20100152418-A1 | Switch-Peptides as Tool for the Study of Fibrillogenesis | IAPP, APP, SPPL2B | CTSS 2143/4885CTSL 558/4885SYK 4267/4885 |
| US-20180346424-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | CTSS 3857/4885CTSL 1713/4885SYK 1037/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | CTSS 471/4885CTSL 223/4885SYK 1914/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | CTSS 320/4885CTSL 100/4885SYK 4442/4885 |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CTSS 448/4885CTSL 210/4885SYK 1947/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | CTSS 1294/4885CTSL 1346/4885SYK 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.